Liraglutide Injection Suppliers & Bulk Manufacturers
Available Forms: Pre filled Pen
Available Strengths: 6 mg/mL
Reference Brands: Saxenda®(US & EU)
Category:
Diabetes
Saxenda® mimics GLP-1 to enhance satiety, delay gastric emptying, and reduce calorie intake. It promotes weight loss by regulating appetite and metabolism. Clinically proven for chronic weight management, it helps patients achieve significant BMI reduction. Benefits include improved metabolic parameters and potential cardiovascular protection. Administered once daily via subcutaneous injection.
Liraglutide injection is available in Pre filled Pen
and strengths such as 6 mg/mL.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Liraglutide injection is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Liraglutide injection can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Saxenda® (liraglutide 3 mg), a GLP-1 receptor agonist, is FDA-approved for chronic weight management in adults (BMI ≥30 or ≥27 with comorbidities) and adolescents (12+). The EMA approves it for adults only, with similar BMI criteria. Both regulators mandate a boxed warning for thyroid C-cell tumor risk and contraindicate use in patients with personal/family history of MTC or MEN 2. Discontinue if <5% weight loss occurs after 12 weeks. Storage: Refrigerate (2–8°C); stable at ≤30°C (USA) or ≤25°C (EU) post-opening. Platforms like Pharmatradz.com streamline global B2B access to compliant Saxenda® sourcing and licensing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing